Clinical Toxicology Unit, Emergency Department, Prince of Wales Hospital, Sydney, Australia.
New South Wales Poisons Information Centre, Sydney, Australia.
Clin Toxicol (Phila). 2022 Sep;60(9):1063-1066. doi: 10.1080/15563650.2022.2074857. Epub 2022 Jun 7.
Tapentadol is an atypical opioid with mu-receptor affinity and noradrenaline reuptake inhibition approved for use in Australia in 2011. However, data on tapentadol poisoning are scarce.
To investigate tapentadol poisonings and related deaths in Australia.
We performed a retrospective review of tapentadol poisonings from New South Wales Poisons Information Centre (NSWPIC) and three toxicology units in Australia. The National Coronial Information System (NCIS) database was searched to determine the number of tapentadol-related deaths.
Between 2016 and 2020, 220 tapentadol calls were made to NSWPIC, with a 4.5-fold increase in tapentadol exposure calls. The median dose ingested was 575 mg (IQR: 300-1163 mg). Most overdoses included co-ingestions (75%), especially benzodiazepines (26%) and opioids (25%). From Jan 2016 to Dec 2021, 107 patients presented to the three toxicology units with tapentadol poisoning. The median dose ingested was 500 mg (IQR: 200-1400 mg). Most patients took co-ingestants (84%), including benzodiazepines (40%) and opioids (32%). Naloxone was administered in 39 patients (36%), 10 (9%) were intubated and the median length of stay was 18 h (IQR: 9-30). Thirty-five tapentadol-related deaths were recorded within NCIS between Jan 2015 and Oct 2021 with a median age of 51 years (IQR: 42-61 years).
There are increasing tapentadol poisonings and deaths reported to the NSWPIC, three toxicology units, and NCIS in Australia. Most tapentadol poisonings were taken with benzodiazepines and/or other opioids.
盐酸他喷他多是一种具有μ受体亲和力和去甲肾上腺素再摄取抑制作用的新型阿片类药物，于 2011 年在澳大利亚获准使用。然而，关于盐酸他喷他多中毒的数据很少。
调查澳大利亚的盐酸他喷他多中毒和相关死亡情况。
我们对新南威尔士毒物信息中心（NSWPIC）和澳大利亚三个毒理学单位的盐酸他喷他多中毒进行了回顾性研究。国家验尸官信息系统（NCIS）数据库用于确定与盐酸他喷他多相关的死亡人数。
2016 年至 2020 年间，NSWPIC 共接到 220 例盐酸他喷他多中毒电话，暴露于盐酸他喷他多的中毒电话增加了 4.5 倍。摄入的中位数剂量为 575mg（IQR：300-1163mg）。大多数中毒包括合并用药（75%），尤其是苯二氮䓬类药物（26%）和阿片类药物（25%）。从 2016 年 1 月至 2021 年 12 月，有 107 例患者因盐酸他喷他多中毒到三个毒理学单位就诊。摄入的中位数剂量为 500mg（IQR：200-1400mg）。大多数患者服用了合并用药（84%），包括苯二氮䓬类药物（40%）和阿片类药物（32%）。39 例患者（36%）接受了纳洛酮治疗，10 例（9%）进行了气管插管，中位住院时间为 18 小时（IQR：9-30 小时）。2015 年 1 月至 2021 年 10 月期间，NCIS 记录了 35 例与盐酸他喷他多相关的死亡，中位年龄为 51 岁（IQR：42-61 岁）。
澳大利亚的 NSWPIC、三个毒理学单位和 NCIS 报告的盐酸他喷他多中毒和死亡人数不断增加。大多数盐酸他喷他多中毒与苯二氮䓬类药物和/或其他阿片类药物同时使用。
